Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...

Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration ...

Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its target price reduced by Barclays from $55.00 to $26.00 in a report published on Friday,Benzinga reports. Barclays currently has an overweight ...

Handelsbanken Fonder AB lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...

Intellia Therapeutics Inc. is shaking up its Cambridge and Waltham real estate footprints. The gene-editing company h as ...

If you suffered losses exceeding $50,000 in Intellia between July 30, 2024 and January 8, 2025 and would like to discuss your ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) came out with a strong set of yearly numbers that could potentially lead to a re-rate of the stock. Revenues were better than expected, with US$58m in revenue ...

Intellia Therapeutics (NASDAQ:NTLA) traded higher on Thursday as investors cheered pipeline updates the gene-editing biotech ...

Intellia Therapeutics Inc (NTLA) reports robust pipeline progress and financial stability, despite increased R&D expenses and ...

Intellia Therapeutics Inc (($NTLA)) has held its Q4 earnings call. Read on for the main highlights of the call. Intellia Therapeutics’ Earnings ...